Geron Corp. (NASDAQ:GERN) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a report released on Friday. The firm presently has a $3.00 price objective on the biopharmaceutical company’s stock. Zacks Investment Research’s price target would indicate a potential upside of 10.70% from the company’s previous close. According to […]
